Overview

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)

Status:
Completed
Trial end date:
2009-02-27
Target enrollment:
Participant gender:
Summary
This is a Phase 1, pharmacokinetic and pharmacodynamic study of intravenous and subcutaneous administered golimumab in patients with rheumatoid arthritis.
Phase:
Phase 1
Details
Lead Sponsor:
Centocor, Inc.
Treatments:
Antibodies, Monoclonal
Golimumab